HPV Infection and Cervical Cancer Prevention
Although accreditation for this CE/CME activity has expired, and the posttest is no longer available, you can still read the full article.
Expires September 30, 2014
–
Improved understanding of the central role of human papillomavirus (HPV) in cervical carcinogenesis has led to the development of vaccines and DNA testing for high-risk HPV subtypes. But age-appropriate cytologic screening remains the cornerstone in the prevention and early detection of cervical intraepithelial neoplasia (CIN) and cervical cancer. With prompt diagnosis and treatment of both CIN and early-stage cervical cancer, the prognosis for this disease is excellent.
CONCLUSION
The incidence and prevalence of cervical cancer continue to decline in the US; the majority of cases that arise are due to the lack of knowledge and availability of screening services in underserved areas. Increasing awareness and developing clinics for these under-screened populations would most likely contribute to a further decline in the incidence of CIN and cervical cancer.
Once diagnosed with an HPV infection, women should be informed that the body generally clears these infections within 1 to 2 years. Persistence of a high-risk HPV infection greatly increases the risk for neoplastic tissue transformation. These women need to be followed diligently so that treatment can be implemented at the first signs of a CIN 2 or higher grade lesion. Ultimately, implementing adequate screening techniques allows for early detection of CIN and prevention of cervical cancer.
